{
    "name": "clonidine",
    "comment": "Rx",
    "other_names": [
        "Catapres",
        "Catapres-TTS",
        "Duraclon",
        "Jenloga",
        "Kapvay",
        "Nexiclon XR"
    ],
    "classes": [
        "Alpha2 Agonists",
        "Central-Acting",
        "ADHD Agents"
    ],
    "source": "https://reference.medscape.com/drug/catapres-tts-clonidine-342382",
    "pregnancy": {
        "common": [
            "There is pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, during pregnancy; healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866- 961-2388 or visiting ",
            "Prolonged experience with clonidine in pregnant women over several decades, based on published literature, including controlled trials, a retrospective cohort study and case reports, have not identified a drug associated risk of major birth defects, miscarriage, and adverse maternal or fetal outcomes",
            "Based on findings in animal studies revealed that drug may impair fertility in females and males of reproductive potential"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "In animal embryofetal studies, increased resorptions were seen in rats and mice administered oral clonidine hydrochloride from implantation through organogenesis at 10 and 5 times, respectively, the maximum recommended human dose (MRHD) given to adolescents on a mg/m2 basis; no developmental effects were seen in rabbits administered drug during organogenesis at doses up to 3 times the MRHD"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Based on published lactation studies, clonidine hydrochloride is present in human milk at relative infant doses ranging from 4.1 to 8.4% of maternal weight-adjusted dosage; although in most cases, there were no reported adverse effects in breastfed infants exposed to clonidine, there is one case report of sedation, hypotonia, and apnea in an infant exposed to clonidine through breast milk; if an infant is exposed to clonidine hydrochloride through breastmilk, monitor for symptoms of hypotension and bradycardia, such as sedation, lethargy, tachypnea and poor feeding",
            null,
            "Monitor breastfeeding infants exposed to drug through breast milk for symptoms of hypotension and/or bradycardia such as sedation, lethargy, tachypnea, and poor feeding"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Epidural clonidine is not recommended for obstetric postpartum or perioperative pain management because the risk of hemodynamic instability (eg, hypotension, bradycardia) may be unacceptable in this population",
                "Dilute product with strength of 500 mcg/mL prior to use"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Epidural: Hemodynamically unstable patients (risk of severe hypotension)",
                "Do not discontinue suddenly (risk of rebound hypertension)",
                "Patch: May need to remove if severe erythema and/or localized vesicle formation develop at application site or generalized rash; consult physician",
                "Severe coronary insufficiency",
                "May cause xerostomia",
                "Recent MI",
                "Cerebrovascular disease",
                "Chronic renal failure",
                "Raynaud's disease",
                "Thromboangiitis obliterans",
                "History of depression (may exacerbate depression in cancer patients)",
                "May impair ability to perform hazardous tasks",
                "Remove patch before MRI (may cause burns)",
                "Hypotension may occur; usually responsive to IV fluids and, if necessary, appropriate parenterally administered pressor agents",
                "Cardiac conduction abnormalities: Sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block, especially if coadministered with other sympatholytic drugs",
                "Titrate slowly and monitor vital signs frequently in patients at risk for hypotension, heart block, bradycardia, syncope, cardiovascular disease, vascular disease, cerebrovascular disease or chronic renal failure; measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy; avoid concomitant use of drugs with additive effects unless clinically indicated; advise patients to avoid becoming dehydrated or overheated",
                "Epidural administration may result in mild respiratory depression (usually with higher than recommended dose)",
                "Use with caution in cerebrovascular disease",
                "Avoid as first line antihypertensive in the elderly due to high risk for adverse side effects",
                "Children may be particularly susceptible to hypertensive episodes when experiencing GI illnesses that lead to vomiting",
                "Discontinue oral immediate release formulations within 4 hr of surgery; restart as soon as possible following surgery",
                "Due to different pharmacokinetic profiles, oral formulations are not interchangeable with extended release on a mg-mg basis due to different pharmacokinetic profiles"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adagrasib",
            "description": {
                "common": "adagrasib will increase the level or effect of clonidine by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Avoid coadministration of adagrasib, a P-gp inhibitor, with sensitive P-gp substrates unless otherwise  recommended in the prescribing information for these substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "alfentanil",
            "description": {
                "common": "clonidine, alfentanil.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atenolol",
            "description": {
                "common": "clonidine, atenolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "azelastine",
            "description": {
                "common": "clonidine, azelastine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Enhanced CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betaxolol",
            "description": {
                "common": "clonidine, betaxolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "clonidine, bisoprolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bremelanotide",
            "description": {
                "common": "bremelanotide will decrease the level or effect of clonidine by  Other (see comment). Avoid or Use Alternate Drug. Bremelanotide may slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications. Avoid use when taking any oral drug that is dependent on threshold concentrations for efficacy. Interactions listed are representative examples and do not include all possible clinical examples."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brigatinib",
            "description": {
                "common": "brigatinib will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Brigatinib induces CYP3A4 in vitro. Coadministration with CYP3A4 substrates, particularly those with a narrow therapeutic index, can result in decreased concentrations and loss of efficacy. If unable to avoid coadministration, monitor CYP3A4 substrate levels and adjust dose as needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "clonidine, buprenorphine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "clonidine, buprenorphine buccal.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "clonidine, buprenorphine subdermal implant.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "clonidine, buprenorphine transdermal.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "clonidine, buprenorphine, long-acting injection.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "butorphanol",
            "description": {
                "common": "clonidine, butorphanol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcium/magnesium/potassium/sodium oxybates",
            "description": {
                "common": "clonidine, calcium/magnesium/potassium/sodium oxybates.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "codeine",
            "description": {
                "common": "clonidine, codeine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diltiazem",
            "description": {
                "common": "clonidine, diltiazem. unknown mechanism. Avoid or Use Alternate Drug. Reports of sinus bradycardia resulting in hospitalization and pacemaker insertion reported with concomitant use. Possible life-threatening effect, monitor closely."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "esmolol",
            "description": {
                "common": "clonidine, esmolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethanol",
            "description": {
                "common": "clonidine, ethanol.\nEither increases toxicity of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "clonidine, hydrocodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "clonidine, hydromorphone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iobenguane I 131",
            "description": {
                "common": "clonidine will decrease the level or effect of iobenguane I 131 by  Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levobunolol",
            "description": {
                "common": "clonidine, levobunolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofexidine",
            "description": {
                "common": "lofexidine, clonidine.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "lumacaftor/ivacaftor will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Lumacaftor is a strong inducer of CYP3A. Avoid coadministration with sensitive CYP3A substrates or CYP3A substrates with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macimorelin",
            "description": {
                "common": "clonidine, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that may transiently elevate growth hormone (GH) concentrations may impact the accuracy of the macimorelin diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "meperidine",
            "description": {
                "common": "clonidine, meperidine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methadone",
            "description": {
                "common": "clonidine, methadone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "clonidine, metoclopramide intranasal.\nEither increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoprolol",
            "description": {
                "common": "clonidine, metoprolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "mirtazapine decreases effects of clonidine by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Risk of hypertensive urgency."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "mobocertinib will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use is unavoidable, increase CYP3A4 substrate dosage in accordance with its prescribing information."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "morphine",
            "description": {
                "common": "clonidine, morphine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nadolol",
            "description": {
                "common": "clonidine, nadolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "clonidine, nalbuphine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nebivolol",
            "description": {
                "common": "clonidine, nebivolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olopatadine intranasal",
            "description": {
                "common": "clonidine and olopatadine intranasal both increase  sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olutasidenib",
            "description": {
                "common": "olutasidenib will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of olutasidenib (a CYP3A4 inducer) with sensitive CYP3A substrates unless otherwise instructed in substrates prescribing information. If unavoidable, monitor for loss of therapeutic effect of sensitive CYP3A4 substrates."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "opium tincture",
            "description": {
                "common": "clonidine, opium tincture.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "orphenadrine",
            "description": {
                "common": "clonidine, orphenadrine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Enhanced CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxycodone",
            "description": {
                "common": "clonidine, oxycodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "clonidine, oxymorphone.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pacritinib",
            "description": {
                "common": "pacritinib will increase the level or effect of clonidine by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pentazocine",
            "description": {
                "common": "clonidine, pentazocine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perampanel",
            "description": {
                "common": "clonidine, perampanel.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod, clonidine.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Consult cardiologist if considering treatment. Coadministration of ponesimod with drugs that decrease HR may have additive effects on decreasing HR and should generally not be initiated in these patients."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propranolol",
            "description": {
                "common": "clonidine, propranolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "remifentanil",
            "description": {
                "common": "clonidine, remifentanil.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sodium oxybate",
            "description": {
                "common": "clonidine, sodium oxybate.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotalol",
            "description": {
                "common": "clonidine, sotalol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotorasib",
            "description": {
                "common": "sotorasib will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use is unavoidable, refer to the prescribing information of the CYP3A4 substrate for dosage modifications"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sufentanil",
            "description": {
                "common": "clonidine, sufentanil.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "clonidine, sufentanil SL.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tapentadol",
            "description": {
                "common": "clonidine, tapentadol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thalidomide",
            "description": {
                "common": "clonidine, thalidomide.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Enhanced CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "timolol",
            "description": {
                "common": "clonidine, timolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tramadol",
            "description": {
                "common": "clonidine, tramadol.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trimipramine",
            "description": {
                "common": "trimipramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. \nComment: Inhibition of uptake by adrenergic neurons."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yohimbe",
            "description": {
                "common": "yohimbe decreases effects of clonidine by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zolpidem",
            "description": {
                "common": "clonidine, zolpidem.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abrocitinib",
            "description": {
                "common": "abrocitinib will increase the level or effect of clonidine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Monitor and titrate dose of P-gp substrate appropriately."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin increases effects of clonidine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "clonidine, alprazolam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, clonidine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "clonidine, amiodarone.\nEither decreases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration increases risk of bradycardia, sinus arrest, and AV block; monitor heart rate in patients on concomitant drugs that slow heart rate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "clonidine, aripiprazole. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avanafil",
            "description": {
                "common": "avanafil increases effects of clonidine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benperidol",
            "description": {
                "common": "clonidine, benperidol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "blinatumomab",
            "description": {
                "common": "blinatumomab increases levels of clonidine by decreasing metabolism. Modify Therapy/Monitor Closely. Treatment initiation causes transient release of cytokines that may suppress CYP450 enzymes; highest drug-drug interaction risk is during the first 9 days of the first cycle and the first 2 days of the 2nd cycle in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bretylium",
            "description": {
                "common": "clonidine, bretylium.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexanolone",
            "description": {
                "common": "brexanolone, clonidine.\nEither increases toxicity of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brodalumab",
            "description": {
                "common": "brodalumab, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, brodalumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of brodalumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbidopa",
            "description": {
                "common": "carbidopa increases effects of clonidine by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate, clonidine.\nEither increases effects of the other by sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "clonidine, chlordiazepoxide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "clonidine, chlorpromazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "clonidine, citalopram.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clobazam",
            "description": {
                "common": "clonidine, clobazam. Other (see comment). Use Caution/Monitor. \nComment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "clonidine, clonazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Enhanced CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "clonidine, clorazepate.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "clonidine, clozapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "daridorexant",
            "description": {
                "common": "clonidine and daridorexant both increase  sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "dexmethylphenidate increases toxicity of clonidine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "clonidine, diazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "difelikefalin",
            "description": {
                "common": "difelikefalin and clonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxazosin",
            "description": {
                "common": "clonidine, doxazosin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxylamine",
            "description": {
                "common": "clonidine, doxylamine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronabinol",
            "description": {
                "common": "clonidine, dronabinol.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "droperidol",
            "description": {
                "common": "clonidine, droperidol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dulaglutide",
            "description": {
                "common": "dulaglutide, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Dulaglutide slows gastric emptying and may impact absorption of concomitantly administered oral medications; be particularly cautious when coadministered with drugs that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dupilumab",
            "description": {
                "common": "dupilumab, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, dupilumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of dupilumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elacestrant",
            "description": {
                "common": "elacestrant will increase the level or effect of clonidine by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Reduce dose of P-gp substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "eluxadoline increases levels of clonidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution when CYP3A substrates that have a narrow therapeutic index are coadministered with eluxadoline."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine inhaled",
            "description": {
                "common": "clonidine, epinephrine inhaled.\nEither increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "clonidine, escitalopram.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, clonidine.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estazolam",
            "description": {
                "common": "clonidine, estazolam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ferric maltol",
            "description": {
                "common": "ferric maltol, clonidine.\nEither increases levels of the other by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Coadministration of ferric maltol with certain oral medications may decrease the bioavailability of either ferric maltol and some oral drugs. For oral drugs where reductions in bioavailability may cause clinically significant effects on its safety or efficacy, separate administration of ferric maltol from these drugs. Duration of separation may depend on the absorption of the medication concomitantly administered (eg, time to peak concentration,  whether the drug is an immediate or extended release product)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "flibanserin increases levels of clonidine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Increase monitoring of concentrations of drugs transported by P-gp that have a narrow therapeutic index if coadministered with flibanserin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "clonidine, fluoxetine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "clonidine, fluphenazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurazepam",
            "description": {
                "common": "clonidine, flurazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine, clonidine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. CNS derpressant effects enhanced."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "clonidine and ganaxolone both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glycerol phenylbutyrate",
            "description": {
                "common": "glycerol phenylbutyrate will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Glycerol phenylbutyrate is a weak inducer of CYP3A4. Monitor for decreased efficacy of CYP3A4 substrates that have a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "guanfacine",
            "description": {
                "common": "clonidine, guanfacine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "clonidine, haloperidol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "clonidine, hydroxyzine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "clonidine, iloperidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "clonidine, insulin degludec. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Clonidine may either increase or decrease the blood glucose lowering effect of antidiabetic agents; clonidine may also mask hypoglycemic symptoms."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "clonidine, insulin degludec/insulin aspart. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Clonidine may either increase or decrease the blood glucose lowering effect of antidiabetic agents; clonidine may also mask hypoglycemic symptoms."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "clonidine, insulin inhaled. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Clonidine may either increase or decrease the blood glucose lowering effect of antidiabetic agents; clonidine may also mask hypoglycemic symptoms."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "isavuconazonium sulfate will increase the level or effect of clonidine by  Other (see comment). Use Caution/Monitor. Isavuconazonium sulfate, an inhibitor of P-gp and CYP3A4, may increase the effects or levels of sensitive P-gp or CYP3A4 substrates, which may require dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivabradine",
            "description": {
                "common": "ivabradine, clonidine.\nEither decreases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ixekizumab",
            "description": {
                "common": "ixekizumab, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, ixekizumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of ixekizumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, clonidine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "lemborexant, clonidine.\nEither increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "levodopa increases effects of clonidine by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "levomilnacipran decreases effects of clonidine by pharmacodynamic antagonism. Use Caution/Monitor. Because levomilnacipran decreases reuptake of NE, it may antagonize clonidine antihypertensive effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorazepam",
            "description": {
                "common": "clonidine, lorazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine",
            "description": {
                "common": "clonidine, loxapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "clonidine, loxapine inhaled. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone increases effects of clonidine by Other (see comment). Use Caution/Monitor. \nComment: Potential  for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust  dose of  antihypertensive agent as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyldopa",
            "description": {
                "common": "clonidine, methyldopa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metyrosine",
            "description": {
                "common": "clonidine, metyrosine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "midazolam intranasal, clonidine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "milnacipran",
            "description": {
                "common": "milnacipran decreases effects of clonidine by pharmacodynamic antagonism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabilone",
            "description": {
                "common": "clonidine, nabilone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "neratinib",
            "description": {
                "common": "neratinib increases levels of clonidine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Neratinib inhibits P-gp transport. Caution if coadministered with a P-gp substrate with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, clonidine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroprusside sodium",
            "description": {
                "common": "nitroprusside sodium, clonidine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olanzapine",
            "description": {
                "common": "clonidine, olanzapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "omaveloxolone will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Omaveloxolone may reduce systemic exposure of sensitive CYP3A4 substrates. Check prescribing information of substrate if dosage modification is needed.  "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oritavancin",
            "description": {
                "common": "oritavancin will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Oritavancin is a weak CYP3A4 inducer; caution if coadministered with CYP3A4 substrates that have a narrow therapeutic index"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxazepam",
            "description": {
                "common": "clonidine, oxazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "palbociclib",
            "description": {
                "common": "palbociclib will increase the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. The dose of  sensitive CYP3A substrates with a narrow therapeutic index may need to be reduced if coadministered with palbociclib"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paliperidone",
            "description": {
                "common": "clonidine, paliperidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "clonidine, paroxetine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "clonidine, perphenazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimozide",
            "description": {
                "common": "clonidine, pimozide. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitolisant",
            "description": {
                "common": "pitolisant will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Pitolisant is a borderline/weak inducer of CYP3A4. Monitor sensitive CYP3A4 substrates for reduced effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pramipexole",
            "description": {
                "common": "clonidine, pramipexole.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "clonidine, prazosin.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Sympatholytic action may worsen sinus node dysfunction and atrioventricular (AV) block."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "clonidine, prochlorperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "promethazine",
            "description": {
                "common": "clonidine, promethazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quazepam",
            "description": {
                "common": "clonidine, quazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "clonidine, quetiapine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Caution if ribociclib is coadministered with sensitive CYP3A4 substrates that have a narrow therapeutic index. Dose reduction for sensitive CYP3A4 substrates may be needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "risperidone",
            "description": {
                "common": "clonidine, risperidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rolapitant",
            "description": {
                "common": "rolapitant will increase the level or effect of clonidine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Oral rolapitant (P-gp inhibitor) may increase plasma concentrations of P-gp substrates and may result in potential adverse reactions. Monitor possible adverse reactions if concomitant use of P-gp substrates and rolapitant can not be avoided."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b will increase the level or effect of clonidine by  Other (see comment). Use Caution/Monitor. Certain proinflammatory cytokines, including interferons, can suppress CYP450 enzymes resulting in increased exposures of some CYP substrates. Therefore, monitor patients who are receiving concomitant drugs that are CYP450 substrates with a narrow therapeutic index from toxicities to such drugs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropinirole",
            "description": {
                "common": "clonidine, ropinirole.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rotigotine",
            "description": {
                "common": "clonidine, rotigotine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rufinamide",
            "description": {
                "common": "clonidine, rufinamide.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarilumab",
            "description": {
                "common": "sarilumab, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of cytokines such as IL-6. Elevated IL-6 concentration may down-regulate CYP activity, such as in patients with RA, and, hence, increase drug levels compared with subjects without RA. Blockade of IL-6 signaling by IL-6 antagonists (eg, sarilumab) might reverse the inhibitory effect of IL-6 and restore CYP activity, leading to decreased drug concentrations. Caution when initiating or discontinuing sarilumab if coadministered with CYP450 substrates, especially those with a narrow therapeutic index."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "schisandra",
            "description": {
                "common": "schisandra will increase the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secukinumab",
            "description": {
                "common": "secukinumab, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation; thus, secukinumab could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of secukinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "serdexmethylphenidate/dexmethylphenidate increases toxicity of clonidine by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "clonidine, sertraline.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sofosbuvir/velpatasvir",
            "description": {
                "common": "sofosbuvir/velpatasvir increases levels of clonidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Velpatasvir inhibits CYP3A4. Caution if coadministered with drugs with narrow therapeutics indexes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, clonidine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tadalafil",
            "description": {
                "common": "tadalafil increases effects of clonidine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teclistamab",
            "description": {
                "common": "teclistamab will increase the level or effect of clonidine by  altering metabolism. Use Caution/Monitor. Teclistamab causes release of cytokines that may suppress activity of CYP450 enzymes, resulting in increased exposure of CYP substrates. Monitor for increased concentrations or toxicities of sensitive CYP substrates. Adjust dose of CYP substrate drug as needed. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teduglutide",
            "description": {
                "common": "teduglutide increases levels of clonidine by Other (see comment). Use Caution/Monitor. \nComment: Teduglutide may increase absorption of concomitant PO medications; caution with with drugs requiring titration or those with a narrow therapeutic index; dose adjustment may be necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telotristat ethyl",
            "description": {
                "common": "telotristat ethyl will decrease the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Telotristat ethyl induces CYP3A4 and may reduce systemic exposure of sensitive CYP3A4 substrates. Monitor for suboptimal efficacy and consider increasing the dose of the CYP3A4 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temazepam",
            "description": {
                "common": "clonidine, temazepam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thioridazine",
            "description": {
                "common": "clonidine, thioridazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "thiothixene",
            "description": {
                "common": "clonidine, thiothixene. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "timolol",
            "description": {
                "common": "timolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "clonidine, triazolam.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "clonidine, trifluoperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trofinetide",
            "description": {
                "common": "trofinetide will increase the level or effect of clonidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor CYP3A4 substrates for which a small increase in plasma concentration may lead to serious toxicities if coadministered with trofinetide (a weak CYP3A4 inhibitor)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ustekinumab",
            "description": {
                "common": "ustekinumab, clonidine. Other (see comment). Use Caution/Monitor. \nComment: Formation of CYP450 enzymes can be altered by increased levels of certain cytokines during chronic inflammation;  thus, normalizing the formation of CYP450 enzymes. Upon initiation or discontinuation of ustekinumab in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "clonidine, verapamil.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Monitor heart rate in patients receiving concomitant verapamil and clonidine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vilazodone",
            "description": {
                "common": "clonidine, vilazodone.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin will increase the level or effect of clonidine by  P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Coadministration of voclosporin (a P-gp inhibitor) increases exposure and risk of adverse reactions of P-gp substrates. For certain P-gp substrates with a narrow therapeutic window, refer to prescribing information of these substrates for dosage modifications, if needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "clonidine, vortioxetine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration enhances CNS depressant effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "xipamide",
            "description": {
                "common": "xipamide increases effects of clonidine by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "clonidine, ziprasidone. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zotepine",
            "description": {
                "common": "clonidine, zotepine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acarbose",
            "description": {
                "common": "clonidine decreases effects of acarbose by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "agrimony",
            "description": {
                "common": "agrimony increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "clonidine decreases effects of chlorpropamide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "clonidine increases levels of cyclosporine by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "forskolin",
            "description": {
                "common": "forskolin increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glimepiride",
            "description": {
                "common": "clonidine decreases effects of glimepiride by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glipizide",
            "description": {
                "common": "clonidine decreases effects of glipizide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "glyburide",
            "description": {
                "common": "clonidine decreases effects of glyburide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "clonidine decreases effects of insulin aspart by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "clonidine, insulin detemir. Other (see comment). Minor/Significance Unknown. \nComment: Decreased symptoms of hypoglycemia.  Mechanism: decreased hypoglycemia induced catecholamine production."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "clonidine, insulin glargine. Other (see comment). Minor/Significance Unknown. \nComment: Decreased symptoms of hypoglycemia.  Mechanism: decreased hypoglycemia induced catecholamine production."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "clonidine, insulin glulisine. Other (see comment). Minor/Significance Unknown. \nComment: Decreased symptoms of hypoglycemia.  Mechanism: decreased hypoglycemia induced catecholamine production."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "clonidine decreases effects of insulin lispro by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "clonidine, insulin NPH. Other (see comment). Minor/Significance Unknown. \nComment: Decreased symptoms of hypoglycemia.  Mechanism: decreased hypoglycemia induced catecholamine production."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "clonidine decreases effects of insulin regular human by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metformin",
            "description": {
                "common": "clonidine decreases effects of metformin by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "miglitol",
            "description": {
                "common": "clonidine decreases effects of miglitol by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nateglinide",
            "description": {
                "common": "clonidine decreases effects of nateglinide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "octacosanol",
            "description": {
                "common": "octacosanol increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "clonidine decreases effects of pioglitazone by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "reishi",
            "description": {
                "common": "reishi increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "repaglinide",
            "description": {
                "common": "clonidine decreases effects of repaglinide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "clonidine decreases effects of rosiglitazone by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "clonidine decreases effects of saxagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shepherd's purse",
            "description": {
                "common": "shepherd's purse, clonidine. Other (see comment). Minor/Significance Unknown. \nComment: Theoretically, shepherd's purse may interfere with BP control."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "clonidine decreases effects of sitagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "clonidine increases levels of tacrolimus by unknown mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tizanidine",
            "description": {
                "common": "tizanidine increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolazamide",
            "description": {
                "common": "clonidine decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "clonidine decreases effects of tolbutamide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "treprostinil",
            "description": {
                "common": "treprostinil increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vildagliptin",
            "description": {
                "common": "clonidine decreases effects of vildagliptin by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infection",
            "percent": null
        },
        {
            "name": "Irritability",
            "percent": null
        },
        {
            "name": "Throat pain",
            "percent": null
        },
        {
            "name": "Nightmares",
            "percent": null
        },
        {
            "name": "Insomnia",
            "percent": null
        },
        {
            "name": "Emotional disorder",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Nasal congestion",
            "percent": null
        }
    ]
}